Drug Detail

Information about SCH 717454 (19D12)

Generic Name
IND	SCH 717454 (19D12)
Brand Name (US)
Manufacturer	Schering-Plough
Drug Type	monoclonal antibody
Delivery	Intravenous
Approval Status	Phase 2
Indications
Overall Strategy	GIST Tumor Based
Strategy	Block related tumor signal paths
Drug Category	IGF1R inhibitor

This is a IGF1R inhibitor in early development. IGF1R is overexpressed in 2/3 of wild-type GISTs and almost all pediatric GISTs.
Patients with wild-type GIST and pediatric GIST may be good candidates for a trial with inhibitors of IGF1R.